LSV Asset Management
ADMA icon

LSV Asset Management’s ADMA Biologics ADMA Stock Holding History

LSV Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,300
Closed -$1.59M – 810
2025
Q1 		$1.59M Hold
80,300
– – ﹤0.01% 585
2024
Q4 		$1.38M Sell
80,300
-43,996
-35% -$828K ﹤0.01% 583
2024
Q3 		$2.48M Sell
124,296
-57,012
-31% -$887K 0.01% 561
2024
Q2 		$2.03M Buy
181,308
+25,608
+16% +$215K ﹤0.01% 603
2024
Q1 		$1.03M Buy
+155,700
New +$851K ﹤0.01% 681

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

LSV Asset Management's ADMA Position: Q2 2025 in Review

LSV Asset Management sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 80,300 shares — an estimated $1.59M sold.

LSV Asset Management first reported a position in ADMA in Q1 2024 and held it in 5 quarters. The position peaked at $2.48M in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • LSV Asset Management reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • LSV Asset Management sold 80,300 ADMA Biologics shares in Q2 2025, an estimated $1.59M.
  • LSV Asset Management first reported a position in ADMA Biologics in Q1 2024 and held it in 5 quarters.
  • LSV Asset Management's ADMA Biologics position peaked at $2.48M in Q3 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on LSV Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.